CWAN vs NVDA

CWAN exhibits a critical disconnect between explosive top-line growth and fundamental financial health, evidenced by a weak Piotroski F-Score of 2/9. While revenue growth is an impressive 72% YoY, the valuation is severely stretched with a PEG ratio of 10.15 and a Price/Sales ratio of 9.83. This fundamental weakness is compounded by aggressive insider selling from the CEO, CFO, and CTO, and a bearish technical trend. Despite a consistent track record of earnings beats, the lack of GAAP profitability and poor deterministic health scores suggest the stock is significantly overvalued.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.